Literature DB >> 10987297

Natural T-cell response against MHC class I epitopes of epithelial cell adhesion molecule, her-2/neu, and carcinoembryonic antigen in patients with colorectal cancer.

D Nagorsen1, U Keilholz, L Rivoltini, A Schmittel, A Letsch, A M Asemissen, G Berger, H J Buhr, E Thiel, C Scheibenbogen.   

Abstract

The antigens epithelial cell adhesion molecule (Ep-CAM), her-2/neu, and carcinoembryonic antigen (CEA) are potential T-cell targets in antigen-specific vaccination-based cancer therapy. We performed this study to evaluate whether a natural specific T-cell response against these tumor-associated antigens (TAAs) already exists in patients with colorectal carcinoma (CRC). We used the IFN-gamma ELISPOT assay to detect circulating TAA-reactive T cells directly ex vivo in unstimulated peripheral blood mononuclear cells. We analyzed the T-cell response in peripheral blood mononuclear cells of 22 HLA-A2-positive patients with CRC and 8 HLA-A2-positive healthy subjects against 3 HLA A2-restricted peptide epitopes of the TAAs Ep-CAM (GLKAGVIAV), her-2/neu (IISAVVGIL), and CEA (YLSGANLNL). Seven of 22 patients but none of the 8 healthy subjects had T cells specifically secreting IFN-gamma in response to one to three of these antigens (n = 4, Ep-CAM; n = 5, her-2/neu; n = 6, CEA). In three of the seven responding patients, TAA-reactive T cells were further characterized by flow cytometry. In all three patients, the majority of these T cells have a CD3+CD8+IFN-gamma+CD69+CD45RA+ phenotype, resembling activated effector-type T cells. T-cell responses occurred only in patients with metastatic disease (Dukes' stages C and D). The results of this study indicate that natural T-cell responses against TAAs occur in approximately one-half of CRC patients with involvement of lymph nodes or distant metastases, but not in CRC patients with disease confined to the intestinum.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10987297

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  29 in total

1.  Tumor infiltrating T lymphocytes in colorectal cancer: Tumor-selective activation and cytotoxic activity in situ.

Authors:  Moritz Koch; Philipp Beckhove; Jan Op den Winkel; Daniel Autenrieth; Philipp Wagner; Daniel Nummer; Sebastian Specht; Dalibor Antolovic; Luis Galindo; Friedrich H Schmitz-Winnenthal; Volker Schirrmacher; Markus W Büchler; Jürgen Weitz
Journal:  Ann Surg       Date:  2006-12       Impact factor: 12.969

2.  Unique ectopic lymph node-like structures present in human primary colorectal carcinoma are identified by immune gene array profiling.

Authors:  Domenico Coppola; Michael Nebozhyn; Farah Khalil; Hongyue Dai; Timothy Yeatman; Andrey Loboda; James J Mulé
Journal:  Am J Pathol       Date:  2011-05-03       Impact factor: 4.307

3.  Therapeutic vaccines for gastrointestinal cancers.

Authors:  Osama E Rahma; Samir N Khleif
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-08

4.  Ex-vivo analysis of CD8+ T cells infiltrating colorectal tumors identifies a major effector-memory subset with low perforin content.

Authors:  Sheng-Wei Ye; Yu Wang; Danila Valmori; Maha Ayyoub; Yan Han; Xiao-Lan Xu; Ai-Lian Zhao; Li Qu; Sacha Gnjatic; Gerd Ritter; Lloyd J Old; Jin Gu
Journal:  J Clin Immunol       Date:  2006-09-12       Impact factor: 8.317

Review 5.  MHC class I antigen presentation and implications for developing a new generation of therapeutic vaccines.

Authors:  Joseph D Comber; Ramila Philip
Journal:  Ther Adv Vaccines       Date:  2014-05

6.  CD4+ T cell responses to HLA-DP5-restricted wild-type sequence p53 peptides in patients with head and neck cancer.

Authors:  Kazuaki Chikamatsu; Koichi Sakakura; Goro Takahashi; Atsushi Okamoto; Nobuhiko Furuya; Theresa L Whiteside; Albert B DeLeo; Keisuke Masuyama
Journal:  Cancer Immunol Immunother       Date:  2009-01-28       Impact factor: 6.968

7.  Dendritic cell-based immunotherapy for colon cancer using an HLA-A*0201-restricted cytotoxic T-lymphocyte epitope from tumor-associated antigen 90K.

Authors:  Ji Hee Lee; Myong-Suk Park; Jun-Eul Hwang; Sang-Hee Cho; Woo-Kyun Bae; Hyun-Jeong Shim; Dae-Eun Kim; Ik-Joo Chung
Journal:  Cell Mol Immunol       Date:  2013-03-25       Impact factor: 11.530

8.  Comparison of T-cell receptor repertoire restriction in blood and tumor tissue of colorectal cancer patients.

Authors:  Sebastian Ochsenreither; Alberto Fusi; Susanne Wojtke; Antonia Busse; Natascha C Nüssler; Eckhard Thiel; Ulrich Keilholz; Dirk Nagorsen
Journal:  J Transl Med       Date:  2010-04-12       Impact factor: 5.531

9.  Increased expression of CEA and MHC class I in colorectal cancer cell lines exposed to chemotherapy drugs.

Authors:  Shunroh Ohtsukasa; Satoshi Okabe; Hironori Yamashita; Takehisa Iwai; Kenichi Sugihara
Journal:  J Cancer Res Clin Oncol       Date:  2003-10-15       Impact factor: 4.553

10.  Immunogenicity and therapeutic efficacy of a dual-component genetic cancer vaccine cotargeting carcinoembryonic antigen and HER2/neu in preclinical models.

Authors:  Luigi Aurisicchio; Daniela Peruzzi; Gloria Koo; Wei-Zen Wei; Nicola La Monica; Gennaro Ciliberto
Journal:  Hum Gene Ther       Date:  2013-12-21       Impact factor: 5.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.